Cefprozil 250 mg (Cefprozil Hydrate)

Adult dose

○ Adults (13 years and older)\n1) For pharyngitis and tonsillitis among upper respiratory tract infections, administer cefprozil hydrate 500mg (potency) per dose every 24 hours; for acute sinusitis, administer 250mg (potency) or 500mg (potency) every 12 hours (an increase in dose is necessary for moderate or more severe infections).\n2) For bacterial superinfection of acute bronchitis or bacterial exacerbation of chronic bronchitis among lower respiratory tract infections, administer 500mg (potency) of this drug per dose every 12 hours.\n3) For uncomplicated skin and soft tissue infections, administer 250mg (potency) of this drug per dose every 12 hours [or 500mg (potency) every 24 hours], or administer 500mg (potency) every 12 hours according to the symptoms.\n4) For uncomplicated urinary tract infections, administer 500mg (potency) of this drug every 24 hours.\n<Duration of administration>\nTreatment is generally administered for about 10 days; however, for pharyngitis/tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic), administer for 10 days or longer. For uncomplicated cystitis, administer for about 7 days.\n○ Patients with renal impairment\n1) If creatinine clearance is 30～120mL/min, administer according to the standard dosage and regimen above.\n2) If creatinine clearance is 29mL/min or less, administer 50% of the standard dose at the standard dosing interval. However, some of this drug is removed by hemodialysis, so administer it after hemodialysis is completed.\nOnce reconstituted, store refrigerated and use within 14 days (for syrup only).

Child dose

○ Children (2～12 years)\nFor pharyngitis and tonsillitis among upper respiratory tract infections, administer 7.5mg (potency) per Kg of body weight per dose every 12 hours.\nFor uncomplicated skin and soft tissue infections, administer 20mg (potency) per Kg of body weight per dose every 24 hours.\n○ Infants and children (6 months～12 years)\nFor otitis media among upper respiratory tract infections, administer 15mg per Kg of body weight every 12 hours.\nFor acute sinusitis among upper respiratory tract infections, administer 7.5mg per Kg of body weight every 12 hours.\nFor moderate or more severe infections requiring a dose increase, administer 15mg per Kg of body weight every 12 hours.

This drug is a cephalosporin antibiotic and should be avoided in certain patients. It should not be used in patients who have had an allergic reaction to cephalosporin antibiotics. Patients who have allergies to penicillin or other drugs should use this drug with caution, as there may be cross-reactivity between beta-lactam antibiotics. Patients with severe illnesses or impaired renal function should carefully check renal status before administration and reduce the dosage if necessary. Poor renal function may cause the drug to remain in the body for a long time, leading to side effects. Patients with gastrointestinal diseases, especially those with a history of colitis, should also use this drug with caution. This drug contains a dye called Tartrazine, and patients who have had allergic reactions to this component should be cautious. Common gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal pain may occur while taking this drug. There have also been reports of allergic reactions such as liver function abnormalities, skin rashes, and itching. Rarely, central nervous system symptoms such as dizziness, headaches, insomnia, drowsiness, changes in blood levels, or renal function abnormalities may occur. In case of a severe allergic reaction or seizure, discontinue the medication immediately and visit a hospital. Long-term use of this drug may lead to the development of resistant bacteria or overgrowth of other bacteria, so it should only be used for the minimal period necessary. When used in combination with other antibiotics or diuretics, renal toxicity may increase, so caution is advised. Women who are pregnant or nursing should only use this drug if absolutely necessary, and nursing mothers should consider the potential effects on their babies before administration. It is advised not to use in infants under 6 months of age as safety and efficacy have not been established. Elderly patients may require dosage adjustments due to potential renal function decline. This drug may affect the results of certain clinical tests, so caution is needed in interpreting test results. In case of overdose, since it is excreted through the kidneys, patients with impaired renal function may require hemodialysis. Finally, this drug is known to present no risk of carcinogenicity or mutagenicity and does not affect reproductive function.

• Diarrhea
• nausea
• vomiting
• abdominal pain
• increased AST
• increased ALT
• increased ALP
• elevated bilirubin levels
• cholestatic jaundice
• rash

This drug is sensitive to light and should be stored in a container that protects it from light. It is also important to keep the drug at room temperature, between 1 and 30 degrees Celsius, to maintain its effectiveness for an extended period.

Appearance

Pale yellow oblong film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle